Shares of Vodafone Group Plc (NASDAQ:VOD) [Trend Analysis] runs in leading trade, it moving down -0.84% to traded at $24.91. The firm has price volatility of 1.28% for a week and 1.24% for a month. Its beta stands at 0.82 times. Vodafone declared that the launch of Vodafone M-Pesa PAY, a digital payment solution for merchants and retailers to receive cashless payments from consumers. The announcement by the telecom operator is another move by tech companies and service providers in India to boost the digital payments drive in India that received fresh impetus from the recent demonetization initiative.
The company says that retailers and merchants will need to download the Vodafone M-Pesa app, which has been offering payment and money transfer options to end users for a while, and then register themselves as a merchant. They can then notify individual consumers to make payments. Consumers, also using the M-Pesa app, will receive a notification that will let them make the payment using their wallet balance, bank account, credit card, or debit card. Narrow down four to firm performance, its weekly performance was 0.60% and monthly performance was -0.98%. The stock price of VOD is moving up from its 20 days moving average with 0.04% and isolated negatively from 50 days moving average with -4.85%.
Several matter pinch shares of Majesco Entertainment Company (NASDAQ:COOL) [Trend Analysis], as shares moving down -4.16% to $4.15 with a share volume of 321007. Following Majesco Entertainment, ‘s (NASDAQ: COOL) declared that it had signed a definitive merger contract with PolarityTE, Polarity has revealed the first wave of their World Class Clinical Advisory Board, as Drs. Michael Grant, Stephen Milner, and Anand Kumar.
Chairman and CEO, Denver Lough MD, PhD elaborated, “Our goal is to build an entirely new type of regenerative medicine company with PolarityTE. The PolarityTE Clinical Advisory Board will play a critical role in translating our regenerative technology into pragmatic clinical practice, helping us address the realities of the field on a real-time basis. It is this tangible feedback that allows PolarityTE technology to evolve quickly under the guidance of thought leaders in reconstructive surgery and regenerative medicine, while permitting our platform to break into new markets and develop new integrative technologies. We are extremely excited to announce the first tier of our world class clinical advisory board.”
The stock is going forward its 52-week low with 59.00% and moving down from its 52-week high price with -56.99%. To have technical analysis views, liquidity ratio of a company was calculated 4.40. The float short ratio was 2.19%, as compared to sentiment indicator; Short Ratio was 0.14.